Format

Send to

Choose Destination
Expert Rev Vaccines. 2004 Dec;3(6):655-63.

Vaccination with Theratope (STn-KLH) as treatment for breast cancer.

Author information

1
University of Washington School of Medicine, Department of Medicine, and Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. PO Box 19024, D5-390, Seattle, WA 98109-1024, USA. lholmber@fhcrc.org

Abstract

Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated antigens in the laboratory. However, few clinical studies with cancer vaccines have demonstrated convincing clinical responses. Sialyl-Tn is a carbohydrate associated with MUC1. It is a unique tumor-associated antigen, present on many adenocarcinomas including breast, ovarian, colorectal, gastric and pancreatic. Consequently, Sialyl-TN is an ideal candidate for boosting the patient's immune system specifically against a unique tumor-associated antigen. The cancer vaccine Theratope was developed by Biomira, Inc. using a synthetic Sialyl-Tn antigen that emulates the unique carbohydrate on human cancer. Clinical trials have predominantly been carried out in breast cancer patients and these trials are outlined in this profile.

PMID:
15606349
DOI:
10.1586/14760584.3.6.655
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center